Infectious disease
The sticking point for the White House is a provision in the guidance that calls for vaccine manufacturers to follow people participating in late-stage clinical trials for a median of at least two months, starting after they receive a second vaccine shot.
There are over 170 COVID-19 vaccine candidates at various stages of development, and all but a few of them take the traditional intramuscular approach. But could intranasal delivery ease the logistical nightmare we face in exterminating the pandemic across the globe?
Pfizer CEO Albert Bourla responds to COVID-19 being brought into this week’s presidential debate with political terms, rather than scientific facts.
The new high-speed test uses a high-throughput method comprising heat and technology to extract RNA from samples used for COVID-19 RT-PCR molecular testing.
At 74 years old, Trump is in a category of older Americans who are at more vulnerable to infection, and at higher risk of developing more serious symptoms.
AstraZeneca’s Phase III COVID-19 vaccine study in the United States is being further delayed due to the U.S. FDA wanting to take a more thorough look at information related to the trial.
The Serum Institute of India (SII) has agreed to produce and deliver up to an additional 100 million doses of an approved COVID-19 vaccine for citizens of India and neighboring low- and middle-income countries as part of a collaboration with Gavi and the Bill & Melinda Gates Foundation.
Moderna published second interim analysis of its open-label Phase I trial of its COVID-19 vaccine, mRNA-1273, in The New England Journal of Medicine.
Although still preliminary, Regeneron Pharmaceuticals announced early data from its Phase I/II/III trial of its antibody cocktail, REGN-COV2, against COVID-19.
More than one month after the government of Russia announced it approved the world’s first vaccine for COVID-19, it announced it will share preliminary data from the first six weeks of the ongoing Phase III study.
PRESS RELEASES